Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections ...

After previous disappointments with BTK inhibitors, a novel drug in this class is the first to show superiority to an active ...

The benefits of frexalimab in people with relapsing MS have been sustained for up to three years in a clinical trial, data ...

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing ...

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no ...

Please provide your email address to receive an email when new articles are posted on . Data were analyzed from 709 participants given ozanimod or interferon in two different trials trials. At 6 ...

Disease-modifying treatments (DMTs) are the gold standard of multiple sclerosis (MS) therapy. They’ve been extensively researched, leading to an evidence base substantiating their efficacy through ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

MS is due to the body’s defence system, or immune system, attacking the insulating cover of myelin that protects the nerves. This damages the nerves and impairs their ability to pass on electric ...